Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). (Q35978512)

11 August 2017

Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). (English)

1 reference

11 August 2017

1 reference

O'Rourke NP

1

1 reference

11 August 2017

McCloskey EV

2

1 reference

11 August 2017

Rosini S

3

1 reference

11 August 2017

Coleman RE

4

1 reference

11 August 2017

Kanis JA

5

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 May 1994

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

69

1 reference

11 August 2017

5

1 reference

11 August 2017

914-917

1 reference

Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968914

Mechanism of malignant hypercalcaemia in carcinoma of the breast

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968914

Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968914

Pathophysiological aspects and therapeutic approaches of tumoral osteolysis and hypercalcemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968914

Structure-activity relationships of various bisphosphonates

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968914

Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968914

Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968914

Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968914

Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment

11 July 2018

1 reference

12 December 2020

The acute-phase response after bisphosphonate administration

1 reference

12 December 2020

Aminohexane diphosphonate in the treatment of Paget's disease of bone

1 reference

12 December 2020

Side-effects of pamidronate

1 reference

12 December 2020

Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia

1 reference

12 December 2020

Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1994.176

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

8180023

1 reference